The relevance of natural killer (NK) cells and killer immunoglobulin-like receptors (KIR) in hematopoietic stem cell transplantation (HSCT);A relevância das células natural killer (NK) e killer immunoglobulin-like receptors (KIR) no transplante de células-tronco hematopoéticas (TCTH)

Revista Brasileira de Hematologia e Hemoterapia

Volumn 30, Issue 4, 2008, Pages 320-329

  Almeida Oliveira, Aline ^a   Diamond, Hilda R ^a,b  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b Laboratório de Imunologia   (Brazil)

Author keywords

Hematopoietic stem cell transplantation; KIR; Leukemia; NK cells

Indexed keywords

EID: 55749115616     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-84842008000400017     Document Type: Review

References (40)

1. Riddell SR, Berger C, Murata M, Randolph S, Warren EH. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev. 2003;17(3):153-62.
2. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103(3):767-76.
3. Barrett AJ, Rezvani K, Solomon S, Dickinson AM, Wang XN, Stark G et al. New developments in allotransplant immunology. Hematology. Hematology Am Soc Hematol Educ Program. 2003: 350-71.
4. Torelli GF, Guarini A, Maggio R, Alfieri C, Vitale A, Foa R. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission. Haematologica. 2005;90(6):785-92.
5. Keever CA, Small TN, Flomenberg N, Heller G, Pekle K, Black P et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood. 1989;73(5):1340-50.
6. Diamond HR, Souza MH, Bouzas LF, Tabak DG, Campos MM, Câmara FP et al. Deficit of T-cell recovery after allogeneic bone marrow transplantation in chronic myeloid leukemia patients. Anticancer Res. 1995;15(4):1553-60.
7. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 2002;100(6):1935-47.
8. O'Connor GM, Hart OM, Gardiner CM. Putting the natural killer cell in its place. Immunology. 2006;117(1):1-10.
9. Dines I, Rumjanek VM, Persechini PM. What is going on with natural killer cells in HIV infection? Int Arch Allergy Immunol. 2004;133(4):330-9.
10. Raulet DH. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol. 2004;5(10):996-1002.
11. Moretta L, Moretta A. Killer immunoglobulin-like receptors. Curr Opin Immunol. 2004;16(5):626-33.
12. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006;20(3):123-37.
13. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94(1):333-9.
14. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-100.
15. Velardi A, Ruggeri L, Alessandro, Moretta, Moretta L. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol. 2002;23(9):438-44.
16. Oshimi K, Oshimi Y, Motoji T, Kobayashi S, Mizoguchi H. Lysis of leukemia and lymphoma cells by autologous and allogeneic interferon-activated blood mononuclear cells. Blood. 1983;61(4):790-8.
17. Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res. 1998;4(11):2859-68.
18. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A, et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood. 2005;105(5):2066-73.
19. Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest. 1998; 101(9):1835-42.
20. JJaksch M, Mattsson J. The pathophysiology of acute graft-versus-host disease. Scand J Immunol. 2005;61(5):398-409.
21. Ljunggren HG, Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990; 11(7):237-44.
22. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217-51.
23. Bléry M, Olcese L, Vivier E. Early signaling via inhibitory and activating NK receptors. Hum Immunol. 2000;61(1):51-64.
24. Borrego F, Kabat J, Kim DK, Lieto L, Maasho K, Peña J, et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol. 2002 Feb;38(9):637-60.
25. Uhrberg M. The KIR gene family: life in the fast lane of evolution. Eur J Immunol. 2005;35(1):10-5.
26. Carrington, M., Norman, P. The KIR gene cluster. National Library of Medicine, United States of America, NCBI, 2003. Disponível em: 〈http://www.ncbi.nlm.nih.gov/booksbv.fcgi?rid=mono_003.TOC&depth= 2〉. Acesso em 07 mar. 2007.
27. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol. 2001;19:291-330.
28. Witt CS, Christiansen FT. The relevance of natural killer cell human leucocyte antigen epitopes and killer cell immunoglobulin-like receptors in bone marrow transplantation. Vox Sang. 2006;90(1):10-20.
29. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood. 2005;105(11):4416-23.
30. Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25(2):331-42.
31. Shilling HG, McQueen KL, Cheng NW, Shizuru JA, Negrin RS, Parham P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood. 2003;101(9):3730-40.
32. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, et al. Determinants of antileukemia effects of allogeneic NK cells. J J Immunol. 2004;172(1):644-50.
33. Bishara A, De Santis D, Witt CC, Brautbar C, Christiansen FT, Or R, et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens. 2004;63(3):204-11.
34. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood. 2002;100(10):3825-7.
35. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102(3):814-9.
36. Bornhäuser M, Schwerdtfeger R, Martin H, Frank KH, Theuser C, Ehninger G. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood. 2004;103(7):2860-1.
37. Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood. 2005;105(6):2594-600.
38. Hsu KC, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon JD, et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2006;12(8):828-36.
39. Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF, et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood. 2004;103(4):1521-6.
40. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105(12):4878-84.